123194-00-3

Basic information

• Product Name: 4-amino-1-methyl-4-Piperidinecarbonitrile
• Synonyms: 4-amino-1-methyl-4-Piperidinecarbonitrile
• CAS NO: 123194-00-3
• Molecular Formula: C₇H₁₃N₃
• Molecular Weight: 139.19822
• Mol File: 123194-00-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-amino-1-methyl-4-Piperidinecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-amino-1-methyl-4-Piperidinecarbonitrile(123194-00-3)
• EPA Substance Registry System: 4-amino-1-methyl-4-Piperidinecarbonitrile(123194-00-3)

Safety Data

• Hazardous Substances Data: 123194-00-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-amino-1-methyl-4-Piperidinecarbonitrile is used as an intermediate in the synthesis of various drugs and bioactive molecules. Its unique structure and functional groups make it a valuable component in the production of new pharmaceutical compounds.
Used in Organic Synthesis:
4-amino-1-methyl-4-Piperidinecarbonitrile is used as a versatile building block in organic synthesis, enabling the creation of a wide range of chemical compounds and substances.
It is important to handle 4-amino-1-methyl-4-Piperidinecarbonitrile with caution and follow proper safety protocols, as it may pose health hazards if not handled properly.

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 151-50-8 potassium cyanide 
• 7664-41-7 ammonia 
• 773837-37-9 sodium cyanide 
• 41838-46-4 4-Amino-1-methylpiperidine 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 15580-66-2 4-amino-1-methyl-4-piperidinecarboxylic acid 
• 228252-34-4 methyl 4-amino-1-methyl-4-piperidinecarboxylate 
• 125889-78-3 4-aminomethyl-1-methyl-piperidin-4-ylamine 
• 625-77-4 N-acetylacetamide 

Relevant articles and documents

Primary α-tertiary amine synthesis via α-C-H functionalization

A quinone-mediated general synthetic platform for the construction of primary α-tertiary amines from abundant primary α-branched amine starting materials is described. This procedure pivots on the efficient in situ generation of reactive ketimine intermediates and subsequent reaction with carbon-centered nucleophiles such as organomagnesium and organolithium reagents, and TMSCN, creating quaternary centers. Furthermore, extension to reverse polarity photoredox catalysis enables reactivity with electrophiles, via a nucleophilic α-amino radical intermediate. This efficient, broadly applicable and scalable amine-to-amine synthetic platform was successfully applied to library and API synthesis and in the functionalization of drug molecules.

Design and Synthesis of Fsp3-Rich, Bis-Spirocyclic-Based Compound Libraries for Biological Screening

The exploration of innovative chemical space is a critical step in the early phases of drug discovery. Bis-spirocyclic frameworks occur in natural products and other biologically relevant metabolites and show attractive features, such as molecular compactness, structural complexity, and three-dimensional character. A concise approach to the synthesis of bis-spirocyclic-based compound libraries starting from readily available commercial reagents and robust chemical transformations has been developed. A number of novel bis-spirocyclic scaffold examples, as implemented in the European Lead Factory project, is presented.

Identification of a novel class of succinyl-nitrile-based Cathepsin S inhibitors

The synthesis and in vitro activities of a series of succinyl-nitrile-based inhibitors of Cathepsin S are described. Several members of this class show nanomolar inhibition of the target enzyme as well as cellular potency. The inhibitors displaying the greatest potency contain N-alkyl substituted piperidine and pyrrolidine rings spiro-fused to the α-carbon of the P1 residue.

Compounds useful as reversible inhibitors of cysteine proteases

Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.

Novel succinate derivative compounds useful as cysteine protease inhibitors

Disclosed are novel succinate derivative compounds of the formula (I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.

Succinate derivative compounds useful as cysteine protease inhibitors

Disclosed are novel succinate derivative compounds of the formula(I)/(Ia): wherein R1, R2, R3, R4, R5, R6, R7, X and A are defined herein. The compounds are useful as inhibitors of cysteine proteases. Also disclosed are methods of using and methods of making such compounds.

AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XII STR1 wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

METHOD OF INDUCING ANTIANDROGENIC ACTIVITY USING IMIDAZOLIDINES SUBSTITUTED WITH A HETEROCYCLE

Novel imidazoles of the formula STR1 wherein the substituents are as defined in the disclosure and their non-toxic, pharmaceutically acceptable addition salts with acids and bases having antiandrogenic activity.

Spiro compounds containing five-membered rings

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XIII: STR1 wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.